• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hand Dermatitis - Pipeline Review, Q1 2011 - Product Image

Hand Dermatitis - Pipeline Review, Q1 2011

  • ID: 1590077
  • March 2011
  • 19 pages
  • Global Markets Direct

Hand Dermatitis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hand Dermatitis - Pipeline Review, Q1 2011', provides an overview of the Hand Dermatitis therapeutic pipeline. This report provides information on the therapeutic development for Hand Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hand Dermatitis. 'Hand Dermatitis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hand Dermatitis.
- A review of the Hand Dermatitis products under development by companies and universities/research institutes based on information READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hand Dermatitis Overview
Therapeutics Development
An Overview of Pipeline Products for Hand Dermatitis
Hand Dermatitis Therapeutics under Development by Companies
Hand Dermatitis Therapeutics - Products under Development by Companies
Companies Involved in Hand Dermatitis Therapeutics Development
ZARS Pharma, Inc.
Hand Dermatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Hand Dermatitis - Featured News
Nov 02, 2010: Basilea receives milestone payment from distribution agreement for Toctino with Almirall
Oct 14, 2009: Basilea’s Toctino receives marketing authorization in Switzerland
Aug 26, 2009: NICE issues positive final guidance recommending the use of Basilea’s Toctino
Jul 16, 2009: NICE issues positive Final Appraisal Determination recommending the use of Basilea’s Toctino
Apr 29, 2009: Basilea’s Toctino receives marketing authorization in Netherlands
Mar 31, 2009: Basilea expands potential commercial availability of Toctino in Europe
Mar 26, 2009: Basilea’s Toctino (alitretinoin) included in new dermatology treatment guidelines in Germany
Mar 17, 2009: Basilea’s Toctino receives marketing authorization in Austria
Mar 11, 2009: Basilea’s Toctino receives marketing authorization in Belgium and Luxemburg
Mar 09, 2009: Basilea’s Toctino accepted for use by the Scottish Medicines Consortium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hand Dermatitis, Q1 2011
Products under Development for Hand Dermatitis – Comparative Analysis, Q1 2011
ZARS Pharma, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011

List of Figures
Number of Products under Development for Hand Dermatitis, Q1 2011
Products under Development for Hand Dermatitis – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos